| Nov 19 |
Neurogene GAAP EPS of -$1.19 in-line
|
| Nov 18 |
Neurogene Reports Third Quarter 2024 Financial Results and Highlights Recent Updates
|
| Nov 18 |
How A Side Effect Has Wiped Out 73% Of Neurogene's Value In A Week
|
| Nov 18 |
Neurogene stock plunges 36% on NGN-401 study update
|
| Nov 18 |
Neurogene Provides Update on NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
|
| Nov 15 |
Earnings Scheduled For November 15, 2024
|
| Nov 12 |
Top Biotech Neurogene Crashes 44%, Wiping Out Its Sprint On A $200 Million Deal
|
| Nov 12 |
Neurogene Shares Drop 35% on Rett Syndrome Gene Therapy Trial Data
|
| Nov 11 |
Neurogene plummets 35% on gene therapy trial data for Rett syndrome
|
| Nov 11 |
Neurogene Reports Positive Interim Efficacy Data from First Four Low-Dose Pediatric Participants in NGN-401 Gene Therapy Clinical Trial for Rett Syndrome
|
